Meanwhile, back at IPIX*, it will be interesting t

Meanwhile, back at IPIX*, it will be interesting to see whatever numbers we get from the conference that starts tomorrow. I think we have the headlines already, but seeing the specific numbers for the clinical trial results should give us more of an idea of what to expect from the next-phase clinical trials.



*despite efforts to focus the board on a troll